|
Press Releases
All Releases
 |
EnteroMedics Achieves Major Milestones in Global Regulatory and Commercialization Strategy for the Maestro System
Aug 2, 2010
|
16.3 KB |
|
| |
ST. PAUL, MN, Aug 02, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that the Company has received conditional approval for its Investigational Device Exemption (IDE) application with...
|
|
EnteroMedics Reports Second Quarter 2010 Financial Results
Jul 22, 2010
|
15.0 KB |
|
| |
ST. PAUL, MN, Jul 22, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced financial results for the three and six months ended June 30, 2010.
For the three months ended June 30, 2010, ...
|
|
Enteromedics Announces 1-for-6 Reverse Split of Common Stock
Jun 29, 2010
|
12.5 KB |
|
| |
ST. PAUL, MN, Jun 29, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that its Board of Directors has approved a 1-for-6 reverse split of its common stock, to be effective upon the clo...
|
|
Data From EnteroMedics' VBLOC-DM2 ENABLE Study to Be Presented at American Society for Metabolic and Bariatric Surgery Meeting
Jun 22, 2010
|
16.8 KB |
|
| |
ST. PAUL, MN, Jun 22, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that updated clinical results from the Company's VBLOC-DM2 ENABLE (DM2) study will be presented on June 26, 2010 a...
|
|
EnteroMedics Reports First Quarter 2010 Financial Results
Apr 21, 2010
|
14.5 KB |
|
| |
ST. PAUL, MN, Apr 21, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2010.
For the three months ended March 31, 2010, the Co...
|
|
EnteroMedics Extends Neuroblocking Technology Research and Development Collaboration
Mar 17, 2010
|
12.3 KB |
|
| |
ST. PAUL, MN, Mar 17, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has extended its 2005 collaboration agreement with the Mayo Clinic for an additional two years. The collab...
|
|
EnteroMedics Announces Submission of IDE Application for Maestro RC System
Mar 15, 2010
|
12.2 KB |
|
| |
ST. PAUL, MN, Mar 15, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has submitted an Investigational Device Exemption (IDE) application with the US Food and Drug Administrati...
|
|
EnteroMedics Appoints Dr. Scott Shikora as Consulting Chief Medical Officer
Feb 22, 2010
|
12.9 KB |
|
| |
ST. PAUL, MN, Feb 22, 2010 (MARKETWIRE via COMTEX News Network) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today the appointment of Scott A. Shikora, M.D., F.A.C.S, as Consulting Chief Medical Officer. Dr. Shikora is currently ...
|
|
EnteroMedics Reports Fourth Quarter and Full Year 2009 Financial Results
Jan 28, 2010
|
16.2 KB |
|
| |
ST. PAUL, Minn., Jan 28, 2010 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity and other
gastrointestinal disorders, today announced financial results for the
three months and full year ended December 31, 2009.
For the full year 2009, the ...
|
|
EnteroMedics Announces Regulatory Path Forward Following FDA Meeting
Jan 28, 2010
|
12.9 KB |
|
| |
ST. PAUL, Minn., Jan 28, 2010 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM),
the developer of medical devices using neuroblocking technology to treat
obesity and other gastrointestinal disorders, announced today that,
following a recent meeting with the U.S. Food and Drug Administration
(FDA) to discuss the Com...
|
|
EnteroMedics Announces Transfer of its Common Stock to the Nasdaq Capital Market
Jan 21, 2010
|
12.7 KB |
|
| |
ST. PAUL, Minn., Jan 21, 2010 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that it has received approval from the Nasdaq
Stock Market Listing Qualifications Staff to transfer the list...
|
|
EnteroMedics Announces $4.8 Million Financing
Jan 14, 2010
|
12.9 KB |
|
| |
ST. PAUL, Minn., Jan 14, 2010 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
that it has entered into a definitive agreement with institutional
...
|
|
EnteroMedics Announces Weight Loss, Hypertension and Diabetes Data from EMPOWER and ENABLE Studies
Jan 14, 2010
|
17.4 KB |
|
| |
ST. PAUL, Minn., Jan 14, 2010 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today announced clinical results from two studies of VBLOC(R)
vagal blocking therapy, including additional data from its EMPO...
|
|
EnteroMedics to Present at the 28th Annual J.P. Morgan Healthcare Conference
Jan 5, 2010
|
10.8 KB |
|
| |
ST. PAUL, Minn., Jan 05, 2010 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that Mark B. Knudson, Ph.D., Chief Executive
Officer, is scheduled to present at the 28th Annual J.P.
...
|
|
EnteroMedics Receives Notice of NASDAQ Listing Deficiencies
Nov 19, 2009
|
12.6 KB |
|
| |
ST. PAUL, Minn., Nov 19, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, announced today that on November 13, 2009 it received two
Nasdaq Staff Deficiency Letters indicating that, for 30 consecutiv...
|
|
EnteroMedics Announces Preliminary Results from Detailed Review of EMPOWER Study
Nov 12, 2009
|
16.0 KB |
|
| |
ST. PAUL, Minn., Nov 12, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today announced preliminary findings from its ongoing
detailed review of its EMPOWER(TM) study, a randomized, double-blind, ...
|
|
EnteroMedics Announces Reduction in Workforce
Oct 27, 2009
|
11.6 KB |
|
| |
ST. PAUL, Minn., Oct 27, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM) today announced that it has
implemented a plan to reduce its workforce and operating costs in order
to preserve capital and streamline its operations following the
announcement of top-line results from its pivotal EMPOWER study on
Octo...
|
|
EnteroMedics Announces Third Quarter 2009 Financial Results
Oct 23, 2009
|
18.0 KB |
|
| |
ST. PAUL, Minn., Oct 23, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today reported financial results for the three and nine
months ended September 30, 2009.
For the three months ended Septemb...
|
|
EnteroMedics Announces $4.9 Million Financing
Oct 2, 2009
|
12.8 KB |
|
| |
ST. PAUL, Minn., Oct 02, 2009 (BUSINESS WIRE) -- EnteroMedics Inc., (NASDAQ: ETRM), the developer of medical devices
using neuroblocking technology to treat obesity, its associated
co-morbidities, and other gastrointestinal disorders, today announced
that it has entered into a definitive agreement with an institutional
...
|
|
EnteroMedics Announces Preliminary Results of its EMPOWER(TM) Study
Oct 2, 2009
|
12.4 KB |
|
| |
ST. PAUL, Minn., Oct 02, 2009 (BUSINESS WIRE) -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity and other gastrointestinal
disorders, today announced preliminary results from its EMPOWER(TM) Study.
Based on an initial analysis, the study did not meet its pri...
|
|
|
= add release to Briefcase
| |
|
| |
EnteroMedics - 2800 Patton Road - St. Paul,
MN 55113
CAUTION: Investigational device. Limited by Federal law to
investigational use.
This page revised May 2009.
©Copyright 2010 EnteroMedics. All rights
reserved. Nothing in this site, including descriptions of treatments
may be reproduced without written authorization from EnteroMedics.
|
